VXRT - Vaxart ticks lower despite COVID-19 vaccine shows benefit in lung inflammation in animal models

Investors seem to apparently reacting to not no overwhelming data from preclinical study evaluating Vaxart ([[VXRT]] -8.9%) oral vaccine candidate showing the candidate protected against lung inflammation in SARS-CoV-2 hamster models.New data showed that hamsters that received two doses of the vaccine had a substantial reduction in lung inflammation as compared to unvaccinated hamsters.The company also adds that data from its Phase I COVID-19 trial expected to be released next week.Previously, the company announced data from animal study showed a significant 10,000x - 100,000x reduction in lung viral load in hamsters compared to non-vaccinated animals.Last week, VBI vaccines announced preclinical data from similar Hamster Challenge study for its COVID-19 vaccine candidate, VBI-2901. Observations in the vaccinated cohorts include prevention of peak viral replication in the lungs by ~10,000-fold and significantly reduced inflammation in the lungs compared to the placebo cohort.

For further details see:

Vaxart ticks lower despite COVID-19 vaccine shows benefit in lung inflammation in animal models